Exhibit 6.

Use of Utilization Management Tools for Selected Atypical Antipsychotics, Newer Antidepressants and Anticonvulsants for PDPs that Serve Dual Eligibles, 2006–2008

	Of Plans that Cover Drug, % that Require Each Utilization Management Tool
Drug Product	Prior Authorization			Step Therapy
	′06	′07	′08	′06	′07	′08
Antipsychotics
Abilify	14%	14%	12%	0%	5%	7%
Abilify Discmelt	N/A	16%	18%	N/A	5%	7%
Risperdal	11%	0%	0%	0.5%	0%	0%
Risperdal Consta (IM)	26%	17%	15%	0.5%	0%	0%
Risperdal M-TAB ODT	11%	6%	6%	0.5%	0%	0%
Zyprexa	11%	10%	7%	0.5%	3%	7%
Zyprexa IM	23%	16%	7%	0.5%	4%	7%
Zyprexa Zydis	7%	19%	18%	0.5%	0.2%	2%
Antidepressants
Celexa	0%	2%	2%	0%	3%	51%
Citalopram	0%	0%	0%	1%	0%	0%
Lexapro	0%	0%	0%	0%	14%	26%
Cymbalta	15%	1%	2%	0%	24%	33%
Paroxetine	0%	0%	0%	4%	0%	0%
Paxil	0%	2%	2%	0%	3%	51%
Paxil CR	5%	0%	1%	5%	7%	39%
Anticonvulsants
Carbamazepine	0%	0%	0%	0%	0%	0%
Carbamazepine chewable	0%	0%	0%	0%	0%	0%
Tegretol	0%	1%	0%	0%	0%	0%
Tegretol chewable	0%	1%	0%	0%	0%	0%
Lamictal	11%	23%	0%	0%	0%	5%
Lamictal chewable	0%	2%	0%	0%	0%	0%
Lamotragine chewable	5%	14%	0%	0%	0%	5%
Depakote	0%	0%	0%	0%	0%	0%
Depakote ER	0%	1%	0%	0%	0%	0%
Depakote sprinkles	0%	1%	0%	0%	0%	0%
Valproic acid	3%	0%	0%	0%	0%	0%
Valproate IV	6%	2%	1%	0%	0%	0%

Note: The source of these data is the January 2006, 2007, and 2008 CMS Prescription Drug Formulary and Pharmacy Network Files. “N/A” refers to drug products not yet available as of January of the year in question. There were 409 PDPs serving dual eligibles in 2006, 642 in 2007, and 495 in 2008.